Table 1.
Baseline characteristics
| Co-infected (N = 33) | Mono- infected (N = 116) | p-value | |
|---|---|---|---|
| Age, year, median (IQR) | 57 (52–59) | 56 (51–61) | 0.78* |
|
| |||
| Male (% of total) | 26 (78.8%) | 78 (67.2%) | 0.20§ |
|
| |||
| African American (% of total) | 14 (42.4%) | 19 (16.4%) | <0.01§ |
|
| |||
| Previous response to dual therapy (% of total) | <0.01§,θ | ||
| Favorable group | 8 (24.3%) | 58 (50.0%) | |
| Naïve | 3 (9.1%) | 35 (30.2%) | |
| Relapser | 5 (15.2%) | 23 (19.8%) | |
| Non favorable group | 25 (75.8%) | 58 (50.0%) | |
| Non-responder | 21 (63.6%) | 51 (44.0%) | |
| Intolerant | 4 (12.1%) | 7 (6.0%) | |
|
| |||
| Advanced fibrosis/cirrhosis (% of total) | 16 (48.5%) | 40/112 (35.7%) | 0.18§ |
|
| |||
| Baseline HCV viral load, log10 IU/mL, median (IQR) | 6.46 (5.92–7.00) | 6.47 (5.91–6.74) | 0.44† |
|
| |||
| Number of pre-treatment visits, median (range) | 2 (1–4) | 1 (1–5) | <0.01* |
| CD4+ T cell count, cells/μL, median (IQR) | 478 (362–763) | - | - |
|
| |||
| HIV VL (% of total) | |||
| Undetectable/< 20 copies/mL | 24/30 (80%) | - | - |
| < 1000 copies/mL | 30/30(100%) | ||
|
| |||
| ART regimen switch required before triple therapy (% of total) | 17 (51.5%) | - | - |
*
Mann-Whitney U Test,
§
Chi-Square,
θ
Chi-square calculated by comparing favorable and non favorable groups,
†
Student T-test
‡
Fisher’s Exact Test
IQR: interquartile range, VL: viral load, ART: antiretroviral therapy